BACKGROUND: Previous review from randomized controlled trials (RCT) showed that patients with cryptogenic stroke may benefit from patent foramen ovale (PFO) closure. However, the findings from the systematic review were not clear when observational studies were also included. METHODS: We searched MEDLINE, Embase, and Cochrane databases. The primary endpoints were recurrent stroke or transient ischemic attack (TIA). The secondary outcomes were all-cause death, atrial fibrillation (AF), and hemorrhagic events. RESULTS: Five randomized trials and fourteen observational studies (6301 participants) were eligible. PFO closure was superior to medical therapy for stroke prevention risk ratios ([RR], 0.38; 95% CI, 0.24-0.60), but showed increased risk of AF (RR, 4.96; 95% CI, 2.31-10.7). There was no significant difference in TIA recurrence, death, and hemorrhagic events. Subgroup analyses showed that patients with factors such as substantial residual shunt, the presence of atrial septal aneurysm (ASA), male, and age <45 years had a lower risk of recurrent stroke when PFOs were closed. CONCLUSIONS: In patients with cryptogenic stroke, PFO closure does appeared to be superior to medical therapy in stroke prevention, with an increased incidence of AF. Male, age <45 years, substantial residual shunt, and the history of ASA are the factors that will predict the benefit when PFO is closed.
BACKGROUND: Previous review from randomized controlled trials (RCT) showed that patients with cryptogenic stroke may benefit from patent foramen ovale (PFO) closure. However, the findings from the systematic review were not clear when observational studies were also included. METHODS: We searched MEDLINE, Embase, and Cochrane databases. The primary endpoints were recurrent stroke or transient ischemic attack (TIA). The secondary outcomes were all-cause death, atrial fibrillation (AF), and hemorrhagic events. RESULTS: Five randomized trials and fourteen observational studies (6301 participants) were eligible. PFO closure was superior to medical therapy for stroke prevention risk ratios ([RR], 0.38; 95% CI, 0.24-0.60), but showed increased risk of AF (RR, 4.96; 95% CI, 2.31-10.7). There was no significant difference in TIA recurrence, death, and hemorrhagic events. Subgroup analyses showed that patients with factors such as substantial residual shunt, the presence of atrial septal aneurysm (ASA), male, and age <45 years had a lower risk of recurrent stroke when PFOs were closed. CONCLUSIONS: In patients with cryptogenic stroke, PFO closure does appeared to be superior to medical therapy in stroke prevention, with an increased incidence of AF. Male, age <45 years, substantial residual shunt, and the history of ASA are the factors that will predict the benefit when PFO is closed.
Authors: Michael Handke; Andreas Harloff; Manfred Olschewski; Andreas Hetzel; Annette Geibel Journal: N Engl J Med Date: 2007-11-29 Impact factor: 91.245
Authors: Stefan Stortecky; Bruno R da Costa; Heinrich P Mattle; John Carroll; Marius Hornung; Horst Sievert; Sven Trelle; Stephan Windecker; Bernhard Meier; Peter Jüni Journal: Eur Heart J Date: 2014-08-11 Impact factor: 29.983
Authors: Herwig Walter Schuchlenz; Wolfgang Weihs; Andrea Berghold; Anita Lechner; Reinhold Schmidt Journal: Int J Cardiol Date: 2005-05-11 Impact factor: 4.164
Authors: P Cerrato; L Priano; D Imperiale; G Bosco; E Destefanis; A M Villar; M Ribezzo; G P Trevi; B Bergamasco; F Orzan Journal: Neurol Sci Date: 2006-02 Impact factor: 3.307
Authors: Lars Søndergaard; Scott E Kasner; John F Rhodes; Grethe Andersen; Helle K Iversen; Jens E Nielsen-Kudsk; Magnus Settergren; Christina Sjöstrand; Risto O Roine; David Hildick-Smith; J David Spence; Lars Thomassen Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: C Weimar; D N Holle; J Benemann; E Schmid; U Schminke; R L Haberl; H-C Diener; M Goertler Journal: Cerebrovasc Dis Date: 2009-07-24 Impact factor: 2.762